Bayer Pulls Remaining Trasylol From U.S. Market
Bayer AG has yanked the leftover stock of its blood-clotting drug Trasylol from the U.S. market amid increasing fears that the drug may cause kidney failure and increase the risk of...To view the full article, register now.
Already a subscriber? Click here to view full article